# NewLink Genetics (now Lumos Pharma)

Source: https://onco.cc/companies/newlink-genetics/  
OnCo record `newlink-genetics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Iowa biotech that ran the largest pancreatic cancer vaccine trial, IMPRESS, and the IDO inhibitor indoximod programme; it merged into Lumos Pharma in 2020.

## Summary

NewLink Genetics developed the HyperAcute whole-cell vaccine platform, including algenpantucel-L for pancreatic cancer, and the IDO pathway inhibitor indoximod. After IMPRESS and PILLAR failed, the company merged with Lumos Pharma in 2020 and left oncology.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Lumos Pharma
- HQ: Ames, Iowa, United States
- Type: biotech
- Website: https://www.lumos-pharma.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/NewLink_Genetics

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Algenpantucel-L](https://onco.cc/drugs/algenpantucel-l/)

---
JSON: https://onco.cc/api/v1/entities/newlink-genetics.json